Physician profile
Emily A Grisnik
NPI 1144679416
$62,386.07
in general payments reported to CMS, 2019-2025
35 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,929 · 2022: $2,366 · 2023: $5,943 · 2024: $6,489 · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $21K · Food and Beverage: $18K · Travel and Lodging: $9,764 · Consulting Fee: $9,468 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $20,900.00 |
| Food and Beverage | $17,616.58 |
| Travel and Lodging | $9,763.60 |
| Consulting Fee | $9,468.00 |
| Education | $342.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $34,173.08 | 2025 | Vtama, Nexplanon |
| Janssen Biotech, INC. | $4,082.23 | 2021-2025 | Tremfya |
| Abbvie INC. | $3,674.85 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,327.57 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $2,064.21 | 2022-2024 | Vtama |
| Amgen INC. | $1,806.00 | 2021-2025 | Otezla, Enbrel, Otezla |
| Leo Pharma INC. | $1,530.68 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $1,515.49 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $1,282.77 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $1,156.92 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,132.67 | 2021-2025 | |
| Genzyme Corporation | $1,106.99 | 2021-2025 | |
| Botanix Sb INC | $1,104.92 | 2025 | Sofdra |
| Lilly USA, LLC | $987.41 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $963.05 | 2022-2025 | Sotyktu |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Grisnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.